Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Recruiting · NCT07237100 · Registry updated 2025-11-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mirdametinib in Patients With Advanced NF1-mutant Melanoma | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, melanocytic neoplasm, melanoma, metastatic melanoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neuroendocrine neoplasm, neurofibroma, neurofibromatosis, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2025-11-19 | NCT07237100 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Kevin Kim, MD | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| California Pacific Medical Center - Sutter Health | San Francisco | United States | 1 |